Amgen, Merck ally in combination trials
Amgen Inc. and Merck & Co. Inc. are teaming up to conduct a Phase Ib/III safety and efficacy trial of Amgen's CD19 antagonist Blincyto (blinatumomab) in combination with Merck's PD-1 receptor antagonist Keytruda (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL).
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.